Low-density lipoprotein levels are one of the independent determinants of circulating levels of advanced glycation end products in nondiabetic subjects

Clinical Cardiology

Volumn 32, Issue 9, 2009, Pages

  Yamagishi, Sho Ichi ^a   Adachi, Hisashi ^a   Matsui, Takanori ^a   Nakamura, Kazuo ^a   Takeuchi, Masayoshi ^b   Enomoto, Mika ^a   Fukami, Ako ^a   Otsuka, Maki ^a   Kumagae, Shun Ichi ^a   Nanjo, Yasuki ^a   Ueda, Shin Ichiro ^a   Imaizumi, Tsutomu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ANAMNESIS; ARTICLE; BLOOD CHEMISTRY; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; PHYSICAL EXAMINATION;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHOLESTEROL, DIETARY; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; FASTING; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; JAPAN; MALE; MIDDLE AGED; REGRESSION ANALYSIS;

EID: 70249094962     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20532     Document Type: Article

References (19)

1. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest. 1994;70:138-151. (Pubitemid 24090096)
2. Brownlee M. Advanced protein glycosylation in diabetes and aging. Ann Rev Med. 1995;46:223-234.
3. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 2005;11:2279-2299. (Pubitemid 40872698)
4. Yamagishi S, Ueda S, Okuda S. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Des. 2007;13:2832-2836. (Pubitemid 350130976)
5. Koschinsky T, He CJ, Mitsuhashi T, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA. 1997;94:6474-6479. (Pubitemid 27270709)
6. He C, Sabol J, Mitsuhashi T, Vlassara H. Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes. 1999;48:1308-1315. (Pubitemid 29241031)
7. Lin RY, Reis ED, Dore AT, et al. Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis. 2002;163:303-311.
8. Uribarri J, Cai W, Sandu O, et al. Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann NY Acad Sci. 2005;1043:461-466. (Pubitemid 41123934)
9. Yamagishi S, Nakamura K, Matsui T, Sato T, Takeuchi M. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver. Med Hypothese. 2006;67:1463-1464. (Pubitemid 43181635)
10. Grundy SM, Denke MA. Dietary influences on serum lipids and lipoproteins. J Lipid Res. 1990;31:1149-1172. (Pubitemid 20224714)
11. Takeuchi M, Makita Z, Bucala R, et al. Immunological evidence that non-carboxymethyllysine advanced glycation end-products produced from short chain sugars and dicarbonyl compounds in vivo. Molecular Med. 2000;6:114-125.
12. Yamagishi S, Adachi H, Nakamura K, et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism. 2006;55:1227-1231. (Pubitemid 44215942)
13. Nakamura K, Yamagishi S, Matsui T, et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and nondiabetic subjects. Clin Exp Med. 2007;7:188-190.
14. Meerwaldt R, Links T, Graaff R, et al. Simple noninvasive measurement of skin autofluorescence. Ann NY Acad Sci. 2005;1043:290-298. (Pubitemid 41123918)
15. Yamagishi S, Adachi H, Takeuchi M, et al. Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population. Horm Metab Res. 2007;39:845-848. (Pubitemid 350206910)
16. Kilhovd BK, Juutilainen A, Lehto S, et al. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol. 2005;25:815-820. (Pubitemid 40463875)
17. Saisho Y, Komiya N, Hirose H. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan. Diabetes Res Clin Pract. 2006;74:201-203. (Pubitemid 44764907)
18. Yamagishi S, Nakamura K, Matsui T. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med. 2007;7:463-469. (Pubitemid 47244891)
19. Miura J, Yamagishi S, Uchigata Y, et al. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with type 1 diabetes. J Diabetes Complications. 2003;17:16-21. (Pubitemid 36042787)